The U.S. Food and Drug Administration has initiated a recall after identifying current Good Manufacturing Practice (CGMP) deviations. The specific issue involved intermittent exposure to temperature excursions during product storage, which may affect product quality and safety.
Manufacturers are advised to assess affected batches and implement corrective actions to prevent future occurrences.
Actualizaciones regulatorias24 ago 2026•1 min de lectura
FDA Recall: CGMP Deviations Due to Intermittent Temperature Excursions
The FDA has issued a recall citing CGMP deviations caused by intermittent temperature excursions during storage.
Recopilado por el equipo de PharmaCountry · Fuente: FDA.gov
Calificaciones
(0)
(0)
(0)
(0)
(0)
Más artículos
Ver todos los artículosInvestigación e Informes
Global Finished Dosage Manufacturing Landscape 2026
5 oct 2026
Actualizaciones regulatoriasKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 sept 2026
AnálisisPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 sept 2026
Deja tu valoración